Kazuma Ogawa

Prof. Dr. Kazuma Ogawa

Kanazawa University
orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2006 in Nuclear Medicine and Biology
Verified
Journal Article
Closed access
HHHirofumi Hanaoka
Hirofumi Hanaoka
TMTakahiro Mukai
Takahiro Mukai
HTHirokazu Tamamura
Hirokazu Tamamura
TMTomohiko Mori
Tomohiko Mori
SISeigo Ishino
Seigo Ishino
HSHideo Saji
Hideo Saji

10 January 2011 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
HYHsin Hsien Yeh
Hsin Hsien Yeh
Kazuma OgawaKazuma Ogawa
Kazuma Ogawa
JBJulius Balatoni
Julius Balatoni
UMUday Mukhapadhyay
Uday Mukhapadhyay
APAsutosh Pal
Asutosh Pal
JGJuri G. Gelovani
Juri G. Gelovani
The importance of the EGF receptor (EGFR) signaling pathway in the development and progression of nonsmall cell lung carcinomas (NSCLC) is widely recognized. Gene sequencing studies revealed that a majority of tumors responding to EGFR kinase inhibitors harbor activating mutations in the EGFR kinase domain. This underscores the need for novel biomarkers and diagnostic imaging approaches to identify patients who may benefit from particular therapeutic agents and approaches with improved efficacy and safety profiles. To this goal, we developed 4-[(3-iodophenyl)amino]-7-{2-[2-{2-(2-[2-{2-([ 18 F]fluoroethoxy)-ethoxy}-ethoxy]-ethoxy)-ethoxy}-ethoxy]-quinazoline-6-yl-acrylamide ([ 18 F]F-PEG6-IPQA), a radiotracer with increased selectivity and irreversible binding to the active mutant L858R EGFR kinase. We show that PET with [ 18 F]F-PEG6-IPQA in tumor-bearing mice discriminates H3255 NSCLC xenografts expressing L858R mutant EGFR from H441 and PC14 xenografts expressing EGFR or H1975 xenografts with L858R/T790M dual mutation in EGFR kinase domain, which confers resistance to EGFR inhibitors (i.e., gefitinib). The T790M mutation precludes the [ 18 F]F-PEG6-IPQA from irreversible binding to EGFR. These results suggest that PET with [ 18 F]F-PEG6-IPQA could be used for the selection of NSCLC patients for individualized therapy with small molecular inhibitors of EGFR kinase that are currently used in the clinic and have a similar structure (i.e., iressa, gefitinib, and erlotinib).

1 October 2001 in Nuclear Medicine and Biology
Verified
Journal Article
Closed access
HAHiromichi Akizawa
Hiromichi Akizawa
YAYasushi Arano
Yasushi Arano
MMMasaki Mifune
Masaki Mifune
AIAkimasa Iwado
Akimasa Iwado
YSYutaka Saito
Yutaka Saito
HSHideo Saji
Hideo Saji

1 July 2005 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
Kazuma OgawaKazuma Ogawa
Kazuma Ogawa
TMTakahiro Mukai
Takahiro Mukai
YAYasushi Arano
Yasushi Arano
MOMasahiro Ono
Masahiro Ono
HHHirofumi Hanaoka
Hirofumi Hanaoka
HSHideo Saji
Hideo Saji

1 March 2019 in Coordination Chemistry Reviews
Verified
Journal Article
Closed access
KMKenji Mishiro
Kenji Mishiro
HHHirofumi Hanaoka
Hirofumi Hanaoka
AYAiko Yamaguchi
Aiko Yamaguchi
Kazuma OgawaKazuma Ogawa
Kazuma Ogawa

4 July 2023 in Coordination Chemistry Reviews
Verified
Journal Article
Closed access
MZMichał Zabiszak
Michał Zabiszak
JFJustyna Frymark
Justyna Frymark
Kazuma OgawaKazuma Ogawa
Kazuma Ogawa
MSMonika Skrobańska
Monika Skrobańska
MNMartyna Nowak
Martyna Nowak
MKMałgorzata T. Kaczmarek
Małgorzata T. Kaczmarek